Home News LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the U.S.

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the U.S.

the vizz product box
Photos courtesy of LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available in the U.S.

Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through their ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.

“We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.”

VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.

“With VIZZ now available, we’re giving people living with presbyopia a simple, fast-acting way to see up close again,” said Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics. “It’s about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We’re excited to bring this new option to millions who want more freedom in their near vision.”

For more information about VIZZ and full prescribing information, visit VIZZ.com.

 

Read more news from WO here.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

- Advertisment -

Most Popular

Florida Native Returns Home to Open Fort Myers Practice

After spending the early years of her career almost 800 miles away from home and working for others, Maivys Longa, OD, was ready to...

Dr. Michele Andrews Appointed Chief Medical Officer of VSP Vision

Michele Andrews, OD, has been named chief medical officer at VSP Vision™. In the role, Dr. Andrews will provide strategic oversight across all clinical...

Sightview Unveils Fresh Patient Engagement Tools at Vision Expo 2026

Sightview, the only electronic health record and practice management partner focused solely on eye care, showcased two recently updated tools for its eye care-specific...

EssilorLuxottica’s Inaugural SWITCH: Vision Innovation Summit Concludes

EssilorLuxottica hosted its inaugural SWITCH: Vision Innovation Summit for the Americas, gathering more than 1,000 leading doctors, scientists, academia, entrepreneurs and cultural voices to...